Cronos Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cronos Group wird ein jährliches Gewinn- und Umsatzwachstum von 8.3% bzw. 4.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -7.8% betragen.

Wichtige Informationen

8.3%

Wachstumsrate der Gewinne

8.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	4.9%
Zukünftige Eigenkapitalrendite	-7.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Aug 09

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Aug 01

Cronos Group: High Hurdles

May 11

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

Mar 01

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Feb 22

Cronos Group: Still No Reason To Own

Jan 22

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

Nov 08

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

Aug 30

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Jul 12

Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann

Jun 14

Cronos Group: Still Hasn't Launched

May 09

Cronos Group Q1 Earnings Preview

May 06

Cronos: The Most Confusing Cannabis Stock

Apr 28

Cronos: Sitting On Your Hands Is Not A Winning Strategy

Jan 03

Cronos Group (CRON) Investor Presentation - Slideshow

Nov 24

Cronos Is A Buy With Increasing Revenues

Nov 18

Cronos shares rise 5% on solid Q3 beat; top-line +96% boosted by advancement in Canadian/Israeli market

Nov 05

Cronos: Failure To Launch

Nov 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CRON - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	126	-24	N/A	17	2
12/31/2025	133	-11	4	12	4
12/31/2024	113	-29	-3	23	6
9/30/2024	111	-48	17	28	N/A
6/30/2024	102	-57	11	16	N/A
3/31/2024	93	-54	-2	3	N/A
12/31/2023	87	-70	-46	-43	N/A
9/30/2023	85	-101	-86	-84	N/A
6/30/2023	81	-133	-101	-97	N/A
3/31/2023	84	-145	-108	-103	N/A
12/31/2022	87	-155	-94	-89	N/A
9/30/2022	91	-213	-105	-101	N/A
6/30/2022	91	-102	-124	-119	N/A
3/31/2022	85	-263	-147	-141	N/A
12/31/2021	65	-127	-166	-154	N/A
9/30/2021	66	-373	-179	-156	N/A
6/30/2021	57	-381	-181	-153	N/A
3/31/2021	51	-310	-188	-153	N/A
12/31/2020	47	-72	-180	-145	N/A
9/30/2020	37	101	-185	-160	N/A
6/30/2020	31	636	-186	-152	N/A
3/31/2020	29	929	-192	-155	N/A
12/31/2019	24	1,167	-170	-131	N/A
9/30/2019	21	1,089	-131	-59	N/A
6/30/2019	18	479	-130	-49	N/A
3/31/2019	13	293	-104	-11	N/A
12/31/2018	12	-21	-96	-8	N/A
9/30/2018	9	-8	-103	-28	N/A
6/30/2018	7	-1	N/A	-16	N/A
3/31/2018	5	-2	N/A	-13	N/A
12/31/2017	3	-1	N/A	-4	N/A
9/30/2017	4	1	N/A	-4	N/A
6/30/2017	2	0	N/A	-8	N/A
3/31/2017	1	-1	N/A	-6	N/A
12/31/2016	0	-1	N/A	-5	N/A
9/30/2016	2	0	N/A	-3	N/A
6/30/2016	2	0	N/A	-2	N/A
3/31/2016	3	1	N/A	-1	N/A
12/31/2015	2	0	N/A	-1	N/A
9/30/2015	0	-4	N/A	-2	N/A
6/30/2015	-1	-4	N/A	-2	N/A
3/31/2015	-1	-4	N/A	-2	N/A
12/31/2014	-1	-4	N/A	-1	N/A
9/30/2014	0	-2	N/A	-1	N/A
6/30/2014	0	-1	N/A	-1	N/A
12/31/2013	0	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CRON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CRONDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: CRONDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CRON wird voraussichtlich in 3 Jahren unrentabel sein.

Cronos Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date moved forward to 2025

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023

Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023

Recent updates

Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada

Buy Cronos Stock Before It Surges Higher

Cronos Group Inc. Brand Spinach®? Celebrates Summer with New Launches

Cronos Group Inc. Elects Murray Garnick as Director

Cronos Group: An Intriguing Value Opportunity

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Cronos Group Inc., Annual General Meeting, Jun 20, 2024

Cronos Group Inc. Launches Lord Jones Chocolate Fusions

Cronos Stock: Attractive Now With Cannabis Legalization In Germany

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cronos Group: Flush With Cash And Trading Below Book Value

Forecast to breakeven in 2026

Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware Options

Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.

Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.

Forecast to breakeven in 2025

Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis Market

Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full Tilt

Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cronos Reportedly Explores Possible Sale After Attracting Takeover Interest

Cronos Group Inc. Announces Executive Changes

Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Cronos Unveils Its New CBC Product: Spinach FEELZ™ Day Trip Gummies with THC+CBC

Cronos Group Inc Announces Executive Changes

Cronos Group Inc. Announces Final Settlement Agreements with U.S. Securities and Exchange Commission and the Staff of the Ontario Securities Commission

Cronos Group Inc. Announces Executive Changes

Insufficient new directors

Second quarter 2022 earnings: Revenues miss analyst expectations

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Cronos Group: High Hurdles

Cronos Group Inc., Annual General Meeting, Jun 23, 2022

Cronos Group Inc., Annual General Meeting, Jun 23, 2022

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Cronos Group Inc. announced delayed amended 10-Q filing

Cronos Group: Still No Reason To Own

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

Second quarter 2021 earnings released: EPS US$0.15 (vs US$0.31 loss in 2Q 2020)

Executive Officer Puneet Mathur has left the company

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann

Cronos Group: Still Hasn't Launched

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.22 profit in 1Q 2020)

Cronos Group Q1 Earnings Preview

Cronos: The Most Confusing Cannabis Stock

Kristen Bell’s Happy Dance™ Available Now at Ulta Beauty™

Executive Chairman recently sold US$6.3m worth of stock

Insider recently sold US$61k worth of stock

Full year 2020 earnings released: US$0.20 loss per share (vs US$3.76 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: US$11.35

New 90-day high: US$9.06

Investor sentiment improved over the past week

Cronos: Sitting On Your Hands Is Not A Winning Strategy

Market bids up stock over the past week

Cronos Group (CRON) Investor Presentation - Slideshow

Cronos Is A Buy With Increasing Revenues